Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Inventiva S.A.NASDAQ: IVA
Change in Working Capital · Q4 FY2025 · quarter ended Dec 2025
Change in working capital grows 386.0% year over year
Q4 FY2025 change in working capital of €8.16M rose 386.0% year over year. Over 3 fiscal years it compounded at +4.0% a year.
Context
- Change in working capital amounted to 143.1% of revenue in FY2025, up 124.9 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
EUR · from the cash flow
- Latest · FY2025
- 6.42M EUR
- Year-over-year change
- +282.2%
- 4-year CAGR
- +60.0%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | +282.2% |
| FY2024 | 2024-12-31 | 1.68M | -90.3% |
| FY2023 | 2023-12-31 | 17.31M | +202.9% |
| FY2022 | 2022-12-31 | 5.71M | +483.6% |
| FY2021 | 2021-12-31 | 979K | — |
Change in Working Capital vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +282.2% is the 2nd highest of 10, against a peer median of -8.0%.
- Change in working capital amounts to 143.1% of revenue for IVA, versus a peer median of 50.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.76M USD | +146.8% | +80.5% | 50.2% | |
| LTM Mar 2026 | $14.87M USD | -22.8% | +6.9% | 26.6% | |
| LTM Mar 2026 | $13.05M USD | +2413.5% | +184.4% | 39.9% | |
| FY2025 | €6.42M EUR | +282.2% | +4.0% | 143.1% | |
| LTM Mar 2026 | $4.18M USD | -8.0% | +65.7% | — | |
| LTM Mar 2026 | $3.94M USD | -31.6% | -51.0% | 35.2% | |
| LTM Mar 2026 | $3.6M USD | -53.4% | +42.5% | 1601.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $2.27M USD | +139.8% | — | — |
| LTM Mar 2026 | $1.57M USD | +169.6% | — | 2652.5% | |
| LTM Mar 2026 | $913K USD | -86.0% | -48.9% | 51.4% | |
| Peer median (excluding IVA) | — | -8.0% | +42.5% | 50.2% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Depreciation & Amortization | (1.29M) | 1.7M | 2.6M | 5.2M | 3.22M |
| Deferred Income Tax | (3.27M) | (5.26M) | (4.74M) | (4.8M) | (2.3M) |
| Stock-Based Compensation | 2.09M | 2.22M | 3.97M | 3.58M | 26.77M |
| Change in Working Capital | 979K | 5.71M | 17.31M | 1.68M | 6.42M |
| Accounts Receivables | (5.32M) | 3.84M | (5.84M) | 2.81M | 816.45K |
| Inventory | (72K) | 19K | (44K) | 417K | 0 |
| Accounts Payables | 7.6M | 3.54M | 20M | 0 | 2.46M |
| Other Working Capital | (1.23M) | (1.69M) | 3.19M | (1.54M) | 3.15M |
| Other Non-Cash Items | 3.5M | 4.98M | 9.68M | 92.63M | 205.07M |
| Operating Cash Flow | (47.63M) | (44.93M) | (81.61M) | (85.93M) | (100.98M) |
| Capital Expenditures | (534K) | (561K) | (540K) | (333K) | (237.26K) |
| Acquisitions (Net) | 89K | 41K | 0 | 0 | 0 |
| Purchases of Investments | (1.35M) | (1K) | (8.3M) | 0 | (127.69M) |
| Sales of Investments | (89K) | 9.39M | 978K | 9.08M | 0 |
| Other Investing Activities | 90K | 1K | 131K | 75.72K | (1K) |
| Investing Cash Flow | (1.79M) | 8.87M | (7.73M) | 8.75M | (127.93M) |
| Debt Repayment | (28K) | 28.44M | (4.1M) | 19.92M | (5.98M) |
| Common Stock Issued | 25.48M | 8.83M | 28.08M | 57.34M | 237.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (17.73K) | (772.47K) | 5.1M | 68.33M | 236.98K |
| Financing Cash Flow | 25.45M | 37.27M | 29.08M | 145.59M | 232M |
| Effect of Forex Changes | 4.84M | (1.03M) | 445K | 1.24M | 11.08M |
| Net Change in Cash | (19.13M) | 183K | (59.82M) | 69.65M | 14.17M |
| Free Cash Flow | (48.16M) | (45.49M) | (82.15M) | (86.26M) | (101.22M) |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.